To identify the population of patients with atopic dermatitis (AD) treated with conventional systemic therapy in Germany and describe indicators of insufficient disease control within this group, specifically focusing on eligibility criteria for systemic drug therapy.
Key Findings:
The estimated 1-year administrative prevalence of AD in Germany was 2.4%, with the highest prevalence in children aged 0-4 years.
AD-related infections were identified as the most common indicator of insufficient disease control.
Prolonged use of topical treatment and a high number of active flares were also significant indicators of inadequate disease management.
Interpretation:
The study underscores the urgent need for enhanced understanding and characterization of systemic therapy use and disease control in patients with AD, particularly those inadequately managed by conventional systemic treatments.
Limitations:
The study relies on claims data, which may not capture all clinical nuances and patient experiences.
Findings may have limited generalizability beyond the German healthcare system due to specific local practices.
Conclusion:
There is a critical need for improved management strategies for patients with AD, particularly for those inadequately controlled by conventional systemic therapies.
